{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T15:09:14Z","timestamp":1759072154081,"version":"3.41.2"},"reference-count":136,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p>The unprecedented worldwide spread of SARS-CoV-2 has imposed severe challenges on global health care systems. The roll-out and widespread administration of COVID-19 vaccines has been deemed a major milestone in the race to restrict the severity of the infection. Vaccines have as yet not entirely suppressed the relentless progression of the pandemic, due mainly to the emergence of new virus variants, and also secondary to the waning of protective antibody titers over time. Encouragingly, an increasing number of antiviral drugs, such as remdesivir and the newly developed drug combination, Paxlovid<jats:sup>\u00ae<\/jats:sup> (nirmatrelvir\/ritonavir), as well as molnupiravir, have shown significant benefits for COVID-19 patient outcomes. Pre-exposure prophylaxis (PrEP) has been proven to be an effective preventive strategy in high-risk uninfected people exposed to HIV. Building on knowledge from what is already known about the use of PrEP for HIV disease, and from recently gleaned knowledge of antivirals used against COVID-19, we propose that SARS-CoV-2 PrEP, using specific antiviral and adjuvant drugs against SARS-CoV-2, may represent a novel preventive strategy for high-risk populations, including healthcare workers, immunodeficient individuals, and poor vaccine responders. Herein, we critically review the risk factors for severe COVID-19 and discuss PrEP strategies against SARS-CoV-2. In addition, we outline details of candidate anti-SARS-CoV-2 PrEP drugs, thus creating a framework with respect to the development of alternative and\/or complementary strategies to prevent COVID-19, and contributing to the global armamentarium that has been developed to limit SARS-CoV-2 infection, severity, and transmission.<\/jats:p>","DOI":"10.3389\/fpubh.2022.945448","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T07:16:01Z","timestamp":1659942961000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["SARS-CoV-2 pre-exposure prophylaxis: A potential COVID-19 preventive strategy for high-risk populations, including healthcare workers, immunodeficient individuals, and poor vaccine responders"],"prefix":"10.3389","volume":"10","author":[{"given":"Jing","family":"Ouyang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvere D.","family":"Zaongo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay","family":"Harypursat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Routy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaokai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,8]]},"reference":[{"key":"B1","unstructured":"COVID-19 Coronavirus Pandemic2020"},{"key":"B2","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41586-022-04460-3","article-title":"T cell responses to SARS-CoV-2 spike cross-recognize Omicron","volume":"603","author":"Keeton","year":"2022","journal-title":"Nature."},{"key":"B3","doi-asserted-by":"publisher","first-page":"809244","DOI":"10.3389\/fimmu.2021.809244","article-title":"SARS-CoV-2 variants, vaccines, and host immunity","volume":"12","author":"Mistry","year":"2021","journal-title":"Front Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"534","DOI":"10.3390\/life12040534","article-title":"Cellular immune response in patients immunized with three vaccine doses of different vaccination schemes authorized by the chilean ministry of health in January 2022","volume":"12","author":"Tabilo Valenzuela","year":"2022","journal-title":"Life."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1056\/NEJMc2103916","article-title":"Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19","volume":"384","author":"Doria-Rose","year":"2021","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1080\/22221751.2021.1953403","article-title":"Antibody titres decline 3-month post-vaccination with BNT162b2","volume":"10","author":"Favresse","year":"2021","journal-title":"Emerg Microbes Infect."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1126\/science.abj4176","article-title":"Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants","volume":"373","author":"Pegu","year":"2021","journal-title":"Science."},{"key":"B8","doi-asserted-by":"publisher","first-page":"100208","DOI":"10.1016\/j.lanepe.2021.100208","article-title":"Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study","volume":"10","author":"Naaber","year":"2021","journal-title":"Lancet Regional Health Europe."},{"key":"B9","doi-asserted-by":"publisher","first-page":"6984","DOI":"10.1016\/j.vaccine.2021.10.038","article-title":"COVID-19 vaccine - Long term immune decline and breakthrough infections","volume":"39","author":"Khoury","year":"2021","journal-title":"Vaccine."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1002\/jmv.27491","article-title":"Omicron variant (B.1.1.529) of SARS-CoV-2, a global urgent public health alert!","volume":"94","author":"Gao","year":"2022","journal-title":"J Med Virol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1021\/acs.jcim.1c01451","article-title":"Omicron variant (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance","volume":"62","author":"Chen","year":"2022","journal-title":"J Chem Inform Model."},{"key":"B12","doi-asserted-by":"publisher","first-page":"eabn4947","DOI":"10.1126\/science.abn4947","article-title":"Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa","volume":"376","author":"Pulliam","year":"2022","journal-title":"Science."},{"key":"B13","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.cell.2021.12.032","article-title":"The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic","volume":"185","author":"Hoffmann","year":"2022","journal-title":"Cell."},{"key":"B14","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41590-022-01130-4","article-title":"Fighting the SARS-CoV-2 pandemic requires a global approach to understanding the heterogeneity of vaccine responses","volume":"23","author":"Tomalka","year":"2022","journal-title":"Nat Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1136\/gutjnl-2020-323020","article-title":"Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19","volume":"70","author":"Yeoh","year":"2021","journal-title":"Gut."},{"key":"B16","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/S1473-3099(14)70847-3","article-title":"Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study","volume":"14","author":"Grant","year":"2014","journal-title":"Lancet Infect Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1001\/jamainternmed.2015.4683","article-title":"Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services","volume":"176","author":"Liu","year":"2016","journal-title":"JAMA Intern Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","article-title":"Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial","volume":"387","author":"McCormack","year":"2016","journal-title":"Lancet."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1093\/cid\/cix593","article-title":"Redefining human immunodeficiency virus (HIV) preexposure prophylaxis failures","volume":"65","author":"Marcus","year":"2017","journal-title":"Clin Infect Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1093\/cid\/civ778","article-title":"No new HIV infections with increasing use of hiv preexposure prophylaxis in a clinical practice setting","volume":"61","author":"Volk","year":"2015","journal-title":"Clin Infect Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1097\/QAD.0000000000001145","article-title":"Effectiveness and safety of oral HIV preexposure prophylaxis for all populations","volume":"30","author":"Fonner","year":"2016","journal-title":"AIDS."},{"volume-title":"WHO Implementation Tool for Pre-exposure Prophylaxis (PrEP) of HIV Infection. Module 5: Monitoring and Evaluation","year":"2018","key":"B22"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1056\/NEJMc2005696","article-title":"Death from Covid-19 of 23 health care workers in China","volume":"382","author":"Zhan","year":"2020","journal-title":"N Engl J Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e209673","DOI":"10.1001\/jamanetworkopen.2020.9673","article-title":"Prevalence and clinical presentation of health care workers with symptoms of coronavirus disease 2019 in 2 Dutch hospitals during an early phase of the pandemic","volume":"3","author":"Kluytmans-van den Bergh","year":"2020","journal-title":"JAMA Netw Open."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e475","DOI":"10.1016\/S2468-2667(20)30164-X","article-title":"Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study","volume":"5","author":"Nguyen","year":"2020","journal-title":"Lancet Public health."},{"key":"B26","unstructured":"Health and Care Worker Deaths During COVID-192021"},{"key":"B27","unstructured":"Up to 180 000 Health Workers May Have Died From COVID-192021"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e003097","DOI":"10.1136\/bmjgh-2020-003097","article-title":"Infection and mortality of healthcare workers worldwide from COVID-19: a systematic review","volume":"5","author":"Bandyopadhyay","year":"2020","journal-title":"BMJ Global Health."},{"key":"B29","doi-asserted-by":"publisher","first-page":"343","DOI":"10.15585\/mmwr.mm6912e2","volume":"69","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e044640","DOI":"10.1136\/bmjopen-2020-044640","article-title":"Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies","volume":"11","author":"Pijls","year":"2021","journal-title":"BMJ Open."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1080\/13685538.2020.1774748","article-title":"Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies","volume":"23","author":"Parohan","year":"2020","journal-title":"Aging Male."},{"key":"B32","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/all.14657","article-title":"Risk factors for severe and critically ill COVID-19 patients: a review","volume":"76","author":"Gao","year":"2021","journal-title":"Allergy."},{"key":"B33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/andr.12868","article-title":"Why does COVID-19 kill more elderly men than women? Is there a role for testosterone?","volume":"9","author":"Papadopoulos","year":"2021","journal-title":"Andrology."},{"key":"B34","doi-asserted-by":"publisher","first-page":"100630","DOI":"10.1016\/j.eclinm.2020.100630","article-title":"Ethnicity and clinical outcomes in COVID-19: a systematic review and meta-analysis","volume":"29","author":"Sze","year":"2020","journal-title":"EClinicalMedicine."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40249-020-00786-0","article-title":"Risk factors associated with mortality of COVID-19 in 3125 counties of the United States","volume":"10","author":"Tian","year":"2021","journal-title":"Infect Dis Poverty."},{"key":"B36","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1007\/s40615-020-00921-5","article-title":"Association between ethnicity and severe COVID-19 disease: a systematic review and meta-analysis","volume":"8","author":"Raharja","year":"2021","journal-title":"J Racial Ethnic Health Disparities."},{"key":"B38","doi-asserted-by":"publisher","first-page":"54","DOI":"10.2450\/2020.0256-20","article-title":"Relationship between the ABO blood group and COVID-19 susceptibility, severity and mortality in two cohorts of patients","volume":"19","author":"Mu\u00f1iz-Diaz","year":"2021","journal-title":"Blood Transfusion."},{"key":"B39","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/cid\/ciaa1150","article-title":"Relationship between the ABO blood group and the coronavirus disease 2019 (COVID-19) susceptibility","volume":"73","author":"Zhao","year":"2021","journal-title":"Clin Infect Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"5761","DOI":"10.1038\/s41467-020-19623-x","article-title":"Associations between blood type and COVID-19 infection, intubation, and death","volume":"11","author":"Zietz","year":"2020","journal-title":"Nat Commun."},{"key":"B41","doi-asserted-by":"publisher","first-page":"100785","DOI":"10.1016\/j.blre.2020.100785","article-title":"The impact of ABO blood group on COVID-19 infection risk and mortality: a systematic review and meta-analysis","volume":"48","author":"Liu","year":"2021","journal-title":"Blood Rev."},{"key":"B42","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/bjh.16797","article-title":"Association between ABO blood groups and risk of SARS-CoV-2 pneumonia","volume":"190","author":"Li","year":"2020","journal-title":"Br J Haematol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.cca.2020.06.026","article-title":"Relationship between ABO blood group distribution and clinical characteristics in patients with COVID-19","volume":"509","author":"Wu","year":"2020","journal-title":"Clin Chim Acta."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet."},{"key":"B45","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.3390\/jcm9051548","article-title":"Early predictors of clinical deterioration in a cohort of 239 patients hospitalized for Covid-19 infection in Lombardy, Italy","volume":"9","author":"Cecconi","year":"2020","journal-title":"J Clin Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"m1091","DOI":"10.1136\/bmj.m1091","article-title":"Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study","volume":"368","author":"Chen","year":"2020","journal-title":"BMJ."},{"key":"B48","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41440-020-0485-2","article-title":"COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study","volume":"43","author":"Huang","year":"2020","journal-title":"Hypertens Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e3319","DOI":"10.1002\/dmrr.3319","article-title":"Diabetes is a risk factor for the progression and prognosis of COVID-19","volume":"36","author":"Guo","year":"2020","journal-title":"Diabetes Metab Res Rev."},{"key":"B50","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.orcp.2020.06.001","article-title":"Obesity is the comorbidity more strongly associated for Covid-19 in Mexico. A case-control study","volume":"14","author":"Hern\u00e1ndez-Gardu\u00f1o","year":"2020","journal-title":"Obesity Res Clin Pract."},{"key":"B51","unstructured":"COVID-19 Clinical Guidance For the Cardiovascular Care Team2020"},{"key":"B52","unstructured":"COVID-19 Information for Specific Groups of People2021"},{"key":"B53","doi-asserted-by":"publisher","first-page":"8562","DOI":"10.1038\/s41598-021-88130-w","article-title":"A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19","volume":"11","author":"Thakur","year":"2021","journal-title":"Sci Rep."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-144684\/v1","article-title":"Coronavirus (COVID-19): a systematic review and meta-analysis to evaluate the significance of demographics and comorbidities","author":"Bhattacharyya","year":"2021","journal-title":"Res Sq."},{"key":"B55","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1080\/00325481.2020.1786964","article-title":"COVID-19 and comorbidities: a systematic review and meta-analysis","volume":"132","author":"Gold","year":"2020","journal-title":"Postgrad Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1111\/dom.14124","article-title":"Prevalence of co-morbidities and their association with mortality in patients with COVID-19: a systematic review and meta-analysis","volume":"22","author":"Singh","year":"2020","journal-title":"Diabetes Obes Metab."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.dsx.2020.06.064","article-title":"Coronavirus disease (COVID-19): A systematic review and meta-analysis to evaluate the impact of various comorbidities on serious events","volume":"14","author":"Nandy","year":"2020","journal-title":"Diabetes Metab Synd."},{"key":"B58","doi-asserted-by":"publisher","first-page":"138226","DOI":"10.1016\/j.scitotenv.2020.138226","article-title":"Effects of temperature variation and humidity on the death of COVID-19 in Wuhan, China","volume":"724","author":"Ma","year":"2020","journal-title":"Sci Total Environ."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.3390\/ijerph17082801","article-title":"Development of an assessment method for investigating the impact of climate and urban parameters in confirmed cases of COVID-19: a new challenge in sustainable development","volume":"17","author":"Pirouz","year":"2020","journal-title":"Int J Environ Res Public Health."},{"key":"B60","doi-asserted-by":"publisher","first-page":"138862","DOI":"10.1016\/j.scitotenv.2020.138862","article-title":"Temperature significantly changes COVID-19 transmission in (sub)tropical cities of Brazil","volume":"729","author":"Prata","year":"2020","journal-title":"Sci Total Environ."},{"key":"B61","doi-asserted-by":"publisher","first-page":"138810","DOI":"10.1016\/j.scitotenv.2020.138810","article-title":"Impact of weather on COVID-19 pandemic in Turkey","volume":"728","author":"Sahin","year":"2020","journal-title":"Sci Total Environ."},{"key":"B62","doi-asserted-by":"publisher","first-page":"138997","DOI":"10.1016\/j.scitotenv.2020.138997","article-title":"Association between climate variables and global transmission oF SARS-CoV-2","volume":"729","author":"Sobral","year":"2020","journal-title":"Sci Total Environ."},{"key":"B63","doi-asserted-by":"publisher","first-page":"138704","DOI":"10.1016\/j.scitotenv.2020.138704","article-title":"Association between short-term exposure to air pollution and COVID-19 infection: evidence from China","volume":"727","author":"Zhu","year":"2020","journal-title":"Sci Total Environ."},{"key":"B64","doi-asserted-by":"publisher","first-page":"141022","DOI":"10.1016\/j.scitotenv.2020.141022","article-title":"COVID-19 and the environment: a critical review and research agenda","volume":"745","author":"Shakil","year":"2020","journal-title":"Sci Total Environ."},{"key":"B65","doi-asserted-by":"publisher","first-page":"40424","DOI":"10.1007\/s11356-021-12364-4","article-title":"Association between population density and infection rate suggests the importance of social distancing and travel restriction in reducing the COVID-19 pandemic","volume":"28","author":"Yin","year":"2021","journal-title":"Environ Sci Pollut Res Int."},{"key":"B66","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-21-1441","article-title":"The polarity and specificity of antiviral T lymphocyte responses determine susceptibility to SARS-CoV-2 infection in cancer patients and healthy individuals","volume":"12","author":"Fahrner","year":"2022","journal-title":"Cancer Discov."},{"key":"B68","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jaip.2020.09.052","article-title":"Clinical outcomes and features of COVID-19 in patients with primary immunodeficiencies in New York City","volume":"9","author":"Ho","year":"2021","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B69","doi-asserted-by":"publisher","first-page":"727850","DOI":"10.3389\/fimmu.2021.727850","article-title":"Humoral and cellular response following vaccination with the BNT162b2 mRNA COVID-19 vaccine in patients affected by primary immunodeficiencies","volume":"12","author":"Amodio","year":"2021","journal-title":"Front Immunol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1038\/s41418-021-00817-9","article-title":"Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis","volume":"28","author":"Goubet","year":"2021","journal-title":"Cell Death Differ."},{"key":"B71","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jaci.2021.08.031","article-title":"Impaired memory B-cell response to the Pfizer-BioNTech COVID-19 vaccine in patients with common variable immunodeficiency","volume":"149","author":"Fernandez Salinas","year":"2022","journal-title":"J Allergy Clin Immunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s40264-017-0505-6","article-title":"Pre-exposure prophylaxis for HIV prevention: safety concerns","volume":"40","author":"Tetteh","year":"2017","journal-title":"Drug Safety."},{"key":"B73","doi-asserted-by":"publisher","first-page":"200","DOI":"10.18773\/austprescr.2020.057","article-title":"Prescribing pre-exposure prophylaxis for HIV","volume":"43","author":"Bloch","year":"2020","journal-title":"Aust Prescriber."},{"key":"B74","unstructured":"The COVID-19 Treatment Guidelines Panel's Statement on Therapies for High-Risk, Nonhospitalized Patients With Mild to Moderate COVID-192022"},{"key":"B75","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/infdis\/jiab247","article-title":"\u03b2-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells","volume":"224","author":"Zhou","year":"2021","journal-title":"J Infect Dis"},{"key":"B76","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat Struct Mol Biol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"EVIDoa2100044","DOI":"10.1056\/EVIDoa2100044","article-title":"Randomized trial of molnupiravir or placebo in patients hospitalized with Covid-19","volume":"1","author":"Arribas","year":"2022","journal-title":"NEJM Evid."},{"key":"B78","doi-asserted-by":"publisher","first-page":"EVIDoa2100043","DOI":"10.1056\/EVIDoa2100043","article-title":"Phase 2\/3 trial of molnupiravir for treatment of Covid-19 in nonhospitalized adults","volume":"1","author":"Caraco","year":"2022","journal-title":"NEJM Evid."},{"key":"B79","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2021","journal-title":"New Engl J Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"New Engl J Med."},{"key":"B81","doi-asserted-by":"publisher","first-page":"6771","DOI":"10.1073\/pnas.1922083117","article-title":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection","volume":"117","author":"de Wit","year":"2020","journal-title":"Proc Natl Acad Sci USA."},{"key":"B82","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"B83","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat Commun."},{"key":"B84","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1056\/NEJMoa2001191","article-title":"First Case of 2019 novel coronavirus in the United States","volume":"382","author":"Holshue","year":"2020","journal-title":"New Engl J Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3390\/v11040326","article-title":"Mechanism of inhibition of ebola virus RNA-dependent RNA polymerase by remdesivir","volume":"11","author":"Tchesnokov","year":"2019","journal-title":"Viruses."},{"key":"B86","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1002\/asia.201900841","article-title":"New nucleoside analogues for the treatment of hemorrhagic fever virus infections","volume":"14","author":"De Clercq","year":"2019","journal-title":"Chem Asian J."},{"key":"B87","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","article-title":"Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19","volume":"6","author":"Eastman","year":"2020","journal-title":"ACS Central Sci."},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","author":"Sheahan","year":"2017","journal-title":"Sci Trans Med."},{"key":"B89","doi-asserted-by":"publisher","first-page":"e13105","DOI":"10.15252\/emmm.202013105","article-title":"A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2","volume":"13","author":"Simonis","year":"2021","journal-title":"EMBO Mol Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1473-3099(21)00485-0","article-title":"Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial","volume":"22","author":"Ader","year":"2022","journal-title":"Lancet Infect Dis."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"New Engl J Med."},{"key":"B92","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results","volume":"384","author":"Pan","year":"2021","journal-title":"New Engl J Med."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial","volume":"324","author":"Spinner","year":"2020","journal-title":"JAMA."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet."},{"key":"B95","unstructured":"Veklury2021"},{"key":"B96","doi-asserted-by":"publisher","first-page":"eabm3410","DOI":"10.1126\/scitranslmed.abm3410","article-title":"Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice","volume":"14","author":"Sch\u00e4fer","year":"2022","journal-title":"Sci Transl Med."},{"key":"B97","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antiviral Res."},{"key":"B98","doi-asserted-by":"publisher","first-page":"107512","DOI":"10.1016\/j.pharmthera.2020.107512","article-title":"Favipiravir, an anti-influenza drug against life-threatening RNA virus infections","volume":"209","author":"Shiraki","year":"2020","journal-title":"Pharmacol Therap."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering."},{"key":"B100","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijid.2020.11.142","article-title":"Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial","volume":"103","author":"Udwadia","year":"2021","journal-title":"Int J Infect Dis."},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.03.022939","article-title":"Triphosphates of the two components in DESCOVY and TRUVADA are inhibitors of the SARS-CoV-2 polymerase","author":"Jockusch","year":"2020","journal-title":"bioRxiv [Preprint]"},{"key":"B102","doi-asserted-by":"publisher","first-page":"117592","DOI":"10.1016\/j.lfs.2020.117592","article-title":"Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study","volume":"253","author":"Elfiky","year":"2020","journal-title":"Life Sci."},{"key":"B103","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/QAI.0b013e3182185276","article-title":"Tenofovir selectively regulates production of inflammatory cytokines and shifts the IL-12\/IL-10 balance in human primary cells","volume":"57","author":"Melchjorsen","year":"2011","journal-title":"J Acquired Immune Deficiency Synd."},{"key":"B104","doi-asserted-by":"publisher","first-page":"e041471","DOI":"10.1136\/bmjopen-2020-041471","article-title":"Cytokines and their relationship with the severity and prognosis of coronavirus disease 2019 (COVID-19): a retrospective cohort study","volume":"10","author":"Liu","year":"2020","journal-title":"BMJ Open."},{"key":"B105","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.it.2020.10.012","article-title":"A potential role of interleukin 10 in COVID-19 pathogenesis","volume":"42","author":"Lu","year":"2021","journal-title":"Trends Immunol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"536","DOI":"10.7326\/M20-3689","article-title":"Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy : a cohort study","volume":"173","author":"Del Amo","year":"2020","journal-title":"Ann Internal Med."},{"key":"B107","doi-asserted-by":"publisher","first-page":"e2005","DOI":"10.1093\/cid\/ciaa1198","volume":"73","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B108","doi-asserted-by":"publisher","first-page":"ofaa455","DOI":"10.1093\/ofid\/ofaa455","article-title":"Preventive efficacy of tenofovir\/emtricitabine against severe acute respiratory syndrome coronavirus 2 among pre-exposure prophylaxis users","volume":"7","author":"Ayerdi","year":"2020","journal-title":"Open Forum Infect Dis."},{"volume-title":"Drugs and Lactation Database (LactMed)","year":"2006","key":"B109"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science."},{"key":"B111","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax."},{"key":"B112","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1128\/AAC.03011-14","article-title":"Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture","volume":"58","author":"de Wilde","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","article-title":"Treatment with lopinavir\/ritonavir or interferon-\u03b21b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset","volume":"212","author":"Chan","year":"2015","journal-title":"J Infect Dis."},{"key":"B114","first-page":"399","article-title":"Treatment of severe acute respiratory syndrome with lopinavir\/ritonavir: a multicentre retrospective matched cohort study","volume":"9","author":"Chan","year":"2003","journal-title":"Hong Kong Med J."},{"key":"B115","unstructured":"Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-192021"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1111\/ajt.16955","article-title":"Nirmatrelvir\/ritonavir use: managing clinically significant drug-drug interactions with transplant immunosuppressants","volume":"22","author":"Lange","year":"2022","journal-title":"Am J Trans."},{"key":"B117","unstructured":"A Drug Safety and Dose-exploratory Clinical Study of Azvudine Tablets in Patients Who Have Not Received Anti-HIV Treatment (FNC)"},{"key":"B118","doi-asserted-by":"publisher","first-page":"8554","DOI":"10.1021\/acs.jmedchem.0c00940","article-title":"Mechanistic insight into antiretroviral potency of 2'-deoxy-2'-\u03b2-fluoro-4'-azidocytidine (FNC) with a long-lasting effect on HIV-1 prevention","volume":"63","author":"Sun","year":"2020","journal-title":"J Med Chem."},{"key":"B119","doi-asserted-by":"publisher","first-page":"e105617","DOI":"10.1371\/journal.pone.0105617","article-title":"Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS ONE."},{"key":"B120","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41392-021-00835-6","article-title":"Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal Transduction Targeted Ther."},{"key":"B121","doi-asserted-by":"publisher","first-page":"e0142287","DOI":"10.1371\/journal.pone.0142287","article-title":"first long-term behavioral records from Cuvier's Beaked Whales (Ziphius cavirostris) reveal record-breaking dives. PLoS ONE 9(3): e92633","volume":"10","author":"Tyack","year":"2015","journal-title":"PLoS ONE."},{"key":"B122","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1021\/jm801595c","article-title":"The design, synthesis, and antiviral activity of monofluoro and difluoro analogues of 4'-azidocytidine against hepatitis C virus replication: the discovery of 4'-azido-2'-deoxy-2'-fluorocytidine and 4'-azido-2'-dideoxy-2',2'-difluorocytidine","volume":"52","author":"Smith","year":"2009","journal-title":"J Med Chem."},{"key":"B123","doi-asserted-by":"publisher","first-page":"e00204","DOI":"10.1128\/JVI.00204-20","article-title":"The pyrimidine analog FNC potently inhibits the replication of multiple enteroviruses","volume":"94","author":"Xu","year":"2020","journal-title":"J Virol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.3851\/IMP2292","article-title":"Novel nucleoside analogue FNC is effective against both wild-type and lamivudine-resistant HBV clinical isolates","volume":"17","author":"Zhou","year":"2012","journal-title":"Antiviral Ther."},{"key":"B125","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1074\/jbc.M708929200","article-title":"2'-deoxy-4'-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2'-alpha-hydroxyl groups","volume":"283","author":"Klumpp","year":"2008","journal-title":"J Biol Chem"},{"key":"B126","doi-asserted-by":"publisher","first-page":"2001435","DOI":"10.1002\/advs.202001435","article-title":"A randomized, open-label, controlled clinical trial of azvudine tablets in the treatment of mild and common COVID-19, a pilot study","volume":"7","author":"Ren","year":"2020","journal-title":"Adv Sci."},{"key":"B127","doi-asserted-by":"publisher","first-page":"e0104521","DOI":"10.1128\/AAC.01045-21","article-title":"Renal and hepatic toxicity analysis of remdesivir formulations: does what is on the inside really count?","volume":"65","author":"Shah","year":"2021","journal-title":"Antimicrob Agents Chemother."},{"key":"B128","doi-asserted-by":"publisher","first-page":"e3990","DOI":"10.1093\/cid\/ciaa1851","article-title":"Remdesivir use in the setting of severe renal impairment: a theoretical concern or real risk?","volume":"73","author":"Pettit","year":"2021","journal-title":"Clin Infect Dis."},{"key":"B129","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2174\/187152611795589663","article-title":"HIV treatment adherence, drug resistance, virologic failure: evolving concepts","volume":"11","author":"Nachega","year":"2011","journal-title":"Infect Disord Drug Targets."},{"key":"B130","doi-asserted-by":"publisher","first-page":"15290","DOI":"10.1038\/s41598-019-51711-x","article-title":"Monotherapy versus combination therapy for multidrug-resistant Gram-negative infections: systematic review and meta-analysis","volume":"9","author":"Schmid","year":"2019","journal-title":"Sci Rep."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMc2120219","article-title":"Resistance mutations in SARS-CoV-2 delta variant after sotrovimab use","volume":"386","author":"Rockett","year":"2022","journal-title":"N Engl J Med."},{"key":"B132","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1056\/NEJMc2031364","article-title":"Persistence and evolution of SARS-CoV-2 in an immunocompromised host","volume":"383","author":"Choi","year":"2020","journal-title":"N Engl J Med."},{"key":"B133","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1016\/j.cell.2021.03.036","article-title":"SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies","volume":"184","author":"Hoffmann","year":"2021","journal-title":"Cell."},{"key":"B134","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1126\/science.abf9302","article-title":"Prospective mapping of viral mutations that escape antibodies used to treat COVID-19","volume":"371","author":"Starr","year":"2021","journal-title":"Science."},{"key":"B135","doi-asserted-by":"publisher","first-page":"858","DOI":"10.7326\/M20-8251","article-title":"Risk compensation and COVID-19 vaccines","volume":"174","author":"Trogen","year":"2021","journal-title":"Ann Intern Med."},{"key":"B136","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1038\/s41598-021-82574-w","article-title":"Risk compensation and face mask mandates during the COVID-19 pandemic","volume":"11","author":"Yan","year":"2021","journal-title":"Sci Rep."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.945448\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T07:16:14Z","timestamp":1659942974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.945448\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,8]]},"references-count":136,"alternative-id":["10.3389\/fpubh.2022.945448"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2022.945448","relation":{},"ISSN":["2296-2565"],"issn-type":[{"type":"electronic","value":"2296-2565"}],"subject":[],"published":{"date-parts":[[2022,8,8]]},"article-number":"945448"}}